Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maud Michaud

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
European Journal of Neurology|May 11, 2023
Caveolinopathy: Clinical, histological, and muscle imaging features and follow-up in a multicenter retrospective cohortEdouard Berling, Camille Verebi, Nadia Venturelli, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 29, 2022
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint InhibitorsAntonio Farina, Macarena Villagrán-García, Nicolás Lundahl Ciano-Petersen, et al.
Neurogenetics|July 5, 2022
Reduced penetrance of an eastern French mutation in ATL1 autosomal-dominant inheritance (SPG3A): extended phenotypic spectrum coupled with brain <sup>18</sup>F-FDG PETArmand Hocquel, Jean-Marie Ravel, Laetitia Lambert, et al.
Brain Communications|November 3, 2025
Mild cognitive dysfunction in hereditary spastic paraplegia 4 disease related to fluorodesoxyglucose cerebral positron emission tomographyRaphaël Miroglio, Armand Hocquel, Jean-Marie Ravel, et al.
Blood|September 22, 2020
CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapiesMarie Le Cann, Françoise Bouhour, Karine Viala, et al.
European Journal of Neurology|April 8, 2024
Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort studyCéline Tard, Françoise Bouhour, Maud Michaud, et al.
European Journal of Neurology|August 15, 2022
Anti-disialosyl-immunoglobulin M chronic autoimmune neuropathies: a nationwide multicenter retrospective studyClaire Peillet, David Adams, Shahram Attarian, et al.
Orphanet Journal of Rare Diseases|December 20, 2024
Spinal muscular atrophy is also a disorder of spermatogenesisArmelle Magot, Arnaud Reignier, Olivier Binois, et al.
Neurology|July 7, 2023
Characteristics of Patients With Late-Onset Pompe Disease in France: Insights From the French Pompe Registry in 2022Claire Lefeuvre, Marie De Antonio, Francoise Bouhour, et al.
Neurology. Genetics|July 20, 2023
Phenotype Presentation and Molecular Diagnostic Yield in Non-5q Spinal Muscular AtrophyGorka Fernández-Eulate, Julian Theuriet, Christopher J Record, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
European Journal of Neurology|May 11, 2023
Caveolinopathy: Clinical, histological, and muscle imaging features and follow-up in a multicenter retrospective cohortEdouard Berling, Camille Verebi, Nadia Venturelli, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 29, 2022
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint InhibitorsAntonio Farina, Macarena Villagrán-García, Nicolás Lundahl Ciano-Petersen, et al.
Neurogenetics|July 5, 2022
Reduced penetrance of an eastern French mutation in ATL1 autosomal-dominant inheritance (SPG3A): extended phenotypic spectrum coupled with brain <sup>18</sup>F-FDG PETArmand Hocquel, Jean-Marie Ravel, Laetitia Lambert, et al.
Brain Communications|November 3, 2025
Mild cognitive dysfunction in hereditary spastic paraplegia 4 disease related to fluorodesoxyglucose cerebral positron emission tomographyRaphaël Miroglio, Armand Hocquel, Jean-Marie Ravel, et al.
Blood|September 22, 2020
CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapiesMarie Le Cann, Françoise Bouhour, Karine Viala, et al.
European Journal of Neurology|April 8, 2024
Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort studyCéline Tard, Françoise Bouhour, Maud Michaud, et al.
European Journal of Neurology|August 15, 2022
Anti-disialosyl-immunoglobulin M chronic autoimmune neuropathies: a nationwide multicenter retrospective studyClaire Peillet, David Adams, Shahram Attarian, et al.
Orphanet Journal of Rare Diseases|December 20, 2024
Spinal muscular atrophy is also a disorder of spermatogenesisArmelle Magot, Arnaud Reignier, Olivier Binois, et al.
Neurology|July 7, 2023
Characteristics of Patients With Late-Onset Pompe Disease in France: Insights From the French Pompe Registry in 2022Claire Lefeuvre, Marie De Antonio, Francoise Bouhour, et al.
Neurology. Genetics|July 20, 2023
Phenotype Presentation and Molecular Diagnostic Yield in Non-5q Spinal Muscular AtrophyGorka Fernández-Eulate, Julian Theuriet, Christopher J Record, et al.
Pageof 3